UGT1A1基因多态性与伊立替康化疗毒性关系的研究进展

doi:10.3969/j.issn.1004-583X.2016.01.029

摘要/Abstract

摘要： 消化道肿瘤是严重威胁人类健康的常见肿瘤,目前消化道肿瘤治疗方案多为根治性手术切除后辅以化学治疗。既往消化道肿瘤化疗方案以5-氟尿嘧啶(5-Fu)或其衍生物为主。而近年来研制出如伊立替康、奥沙利铂等细胞毒类药物,使消化道肿瘤患者化疗效果有了很大提高。含伊立替康的化疗方案,治疗效果明显。但同时可能发生严重毒性反应,如严重延迟性腹泻、中性粒细胞减少等。以往对伊立替康所致严重毒性反应分子水平研究较少。近来大量分子水平研究表明伊立替康化疗严重毒性反应与其代谢过程的某些酶基因多态性相关。

关键词: 消化系统肿瘤, 伊立替康, DNA拓扑异构酶类, Ⅰ型, 基因多态性, 药物毒性

中图分类号:

R735

陈文兴, 徐亮, 綦晓龙. UGT1A1基因多态性与伊立替康化疗毒性关系的研究进展[J]. 临床荟萃, 2016, 31(1): 112-116.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.01.029

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I1/112

参考文献

[1] 杨立学,马韬,张俊,等.伊立替康化学治疗的不良反应与UGT1A1* 28基因多态性的关系[J].内科理论与实践,2009,4(4):300-304.
[2] Douillard JY,Cunningham D,Roth AD,et al.Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial[J].Lancet,2000,355(9209):1041-1047.
[3] Toffoli G,Cecchin E,Corona G,et al.Pharmacogenetics of irinotecan[J].Curr Med Chem Anticancer Agents,2003,3(3):225-237.
[4] Champoux JJ.DNA topoisomerases;structure,function,and mechanism[J]. Annu Rev Biochem,2001,70: 369-413.
[5] Ogawara D,Fukuda M,Nakamura Y,et al.Life-threatening toxicity in a patient with UGT1A1*6 heterozygous polymorphism after irinotecan-based chemotherapy:a case report[J].Acta Med Nagasaki,2014,59: 63-65.
[6] 曹凯,司继刚,孙敏,等.伊立替康相关腹泻及粒细胞缺乏致死亡[J].中国药物应用与监测,2014,11(1):57-59.
[7] 江伟,陈振东.FOLFIRI方案治疗老年结直肠癌安全性临床观察[J].安徽医科大学学报,2010,45(2):237-240.
[8] Alimonti A,Gelibter A,Pavese I,et al.New approaches to prevent intestinal toxicity of irinotecan-based regimens[J].Cancer Treat Rev,2004,30(6):555-561.
[9] 季楚舒,何义富,胡冰,等.UGT1A1*28 基因多态性与晚期结直肠癌伊立替康化疗疗效及不良反应的关系[J].肿瘤,2010,30(10):870-874.
[10] 王晖,武晓楠,丁丽,等.伊立替康相关不良反应与UGT1A1基因多态性的关系[J].现代肿瘤医学,2013,21(1):161-163.
[11] Dranitsaris G,Shah A,Spirovski B,et al.Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy:the development of a risk prediction tool[J].Clin Colorectal Cancer,2007,6(5):367-373.
[12] Duffour J,Gourgou S,Desseigne F,et al.Multicentre phase Ⅱ study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer[J].Cancer Chemother Pharmacol,2007,60(3):383-389.
[13] 张新玉,田辉.遗传性非结合型高胆红素血症[J].肝脏,2005,10(1):51-52.
[14] Takahara N,Nakai Y,Isayama H,et al.Uridine diphosphate glucuronosyl transferase1 family polypeptide A1gene(UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer[J].Cancer Chemother Pharmacol,2013,71(1):85-92.
[15] Desai AA,Innocenti F,Ratain MJ.UGT pharmacogenomics:implications for cancer risk and cancer therapeutics[J].Pharmacogenetics,2003,13(8):517-523.
[16] Hirose K,Kozu C,Yamashita K,et al.Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene[J].Oncol Lett,2012,3(3):694-698.
[17] Liu CY,Chen PM,Chiou TJ,et al.UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma[J].Cancer,2008,112(9):1932-1940.
[18] Sanoff HK,Sargent DJ,Green EM,et al.Racial differences in advanced colorectal cancer outcomes and pharmacogenetics:a subgroup analysis of a large randomized clinical trial[J].J Clin Oncol,2009,27(25):4109-4115.
[19] Teh LK,Hashim H,Zakaria ZA,et al.Polymorphisms of UGT1A1*6,UGT1A1*27 & UGT1A1*28 in three major ethnic groups from Malaysia[J].Indian J Med Res,2012,136(2):249-259.
[20] Innocenti F,Undevia SD,Iyer L,et al.Genetic variants in the UDP-glucuronosyl transferase 1A1 gene predict the risk of severe neutropenia of irinotecan[J].J Clin Oncol,2004,22(8):1382-1388.
[21] Wang Y,Shen L,Xu N,et al.UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil[J].World J Gastroenterol,2012,18(45):6635-6644.
[22] Martinez-Balibrea E,Abad A,Martínez-Cardús A,et al.UGT1A1 and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy[J].Br J Cancer,2010,103(4):581-589.
[23] Okuyama Y,Hazama S,Nozawa H,et al.Prospective phase Ⅱ study of FOLFIRI for mCRC in Japan,including the analysis of UGT1A1*28/*6 polymorphisms[J].Jpn J Clin Oncol,2011,41(4):477-482.
[24] Hu ZY,Yu Q,Zhao YS,et al.Dose-dependent association between UGT1A1 *28 polymorphism and irinotecan-induced diarrhea:a meta-analysis[J].Eur J Cancer,2010,46(10):1856-1865.
[25] Schulz C,Heinemann V,Schalhorn A,et al.UGT1A1 gene polymorphism:impact on toxicity and efficacy of irinotecan-based regiments in metastatic colorectal cancer[J].World J Gastroenterol,2009,15(40):5058-5066.
[26] Braun MS,Richman SD,Thompson L,et al.Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer:the FOCUS trial[J]. J Clin Oncol,2009,27(33):5519-5528.
[27] 李虎,黄鹤,刘继红.UT1A1基因启动子多态性与伊立替康化疗毒性作用的关系[J].中华妇产科杂志,2011,46(12):888-891.
[28] Sunakawa Y,Ichikawa W,Fujita K,et al.UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer[J].Cancer Chemother Pharmacol,2011,68(2):279-284.
[29] Fujita K,Sasaki Y.Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy[J].Curr Drug Metab,2007,8(6):554-562.
[30] Minami H,Sai K,Saeki M,et al.Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese:roles of UGT1A1*6 and *28[J].Pharmacogenet Genomics,2007,17(7):497-504.
[31] Yamashita K,Nagashima F,Fujita K,et al.Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer[J].Jpn J Clin Oncol,2011,41(2):204-209.
[32] Satoh T,Ura T,Yamada Y,et al.Genotype-directed,dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms[J].Cancer Sci,2011,102(10):1868-1873.
[33] 徐建明.伊立替康联合氟尿嘧啶治疗晚期结直肠癌的疗效和毒性的预测研究[D].军事医学科学院附属医院,2009.